Caldera Medical announced that it acquired Ethicon’s Gynecare TVT family of products and will transition the products in the coming months.
Ethicon’s Gynecare TVT product line (consisting of TVT, TVT Exact, TVT-O and TVT Abbrevo) provides minimally invasive treatment options for women with stress urinary incontinence. Ethicon is a subsidiary of Johnson & Johnson. The company is part of the Johnson & Johnson MedTech business segment and was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line.
Headquartered in Westlake, California, Caldera Medical is a privately held women’s health medical device company focused on minimally invasive applications.
As part of the acquisition, Caldera Medical will maintain the same manufacturing facility, materials and dedicated manufacturing team behind the TVT products, ensuring a seamless transition for surgeons, patients and partners. Caldera Medical will expand global customer support for TVT over the next several months and invest in advancing care for a greater number of women. Financial terms of the deal were not disclosed.
“This acquisition marks a significant advancement in our mission to transform women’s health,” said Bryon Merade, CEO of Caldera Medical. “By bringing the TVT product line into our portfolio, we reinforce our unwavering commitment to providing safe, effective solutions for surgeons and their patients. We are honored to build on the legacy and expand the reach of this esteemed product family, delivering proven treatments to more women around the world.”
According to data in the LevinPro HC database, this marks the 20th Medical Device transaction of 2025. There were 87 Medical Device acquisitions announced in 2024, and 112 announced in 2023. This is also Caldera Medical’s first acquisition of the year. The company acquired Atlantic Therapeutics in September 2023 and UVision 360 in October 2024.
